Skip to main content

Table 1 Demographic, Disease, and Treatment Characteristics of Study Participants

From: The burden of amyloid light chain amyloidosis on health-related quality of life

  Baseline sample
N = 341
n %
Mean age, years (SD) 60.6 (10.2)
Range, years (median) 23–85 (61)
Gender (n = 340)a
 Male 160 47.1
 Female 180 52.9
Race/ethnicity
 White 304 89.1
 Other 37 10.9
Education (n = 322)a
  ≤ High school diploma or GED® 26 8.1
 Some college but no degree 50 15.5
 A Associate’s degree or technical certificate 49 15.2
 Bachelor’s degree 109 33.9
 Graduate degree 88 27.3
Marital status (n = 330)a
 Married 271 82.1
 Other 59 17.9
Employment status
 Currently employed for pay 115 38.3
US region of residence
 Northeast 68 19.9
 Southeast 56 16.4
 Midwest 54 15.8
 Southwest 24 7.0
 West 81 23.8
 Other/unknown 58 17.0
Mean time since diagnosis, years (SD) 4.5 (4.0)
Range (median) 1 month–28 years (3.5 years)
Time between onset of symptoms and diagnosis
 Less than 6 months 96 28.2
 Between 6 months and 1 year 97 28.4
 Between 1 and 2 years 76 22.3
 Between 2 and 3 years 31 9.1
 More than 3 years 41 12.0
Number of doctors seen before diagnosis
 One 11 3.2
 Two 57 16.7
 Three 60 17.6
 Four 68 19.9
 Five or more 145 42.9
Organs/systems impactedb
 Heart (cardiac) 178 52.2
 Kidney 214 62.8
 Liver 49 14.4
 Nervous system 126 37.0
 Gastrointestinal 148 43.4
 Other 117 34.3
Number of organs involved
 One 95 27.9
 Two 89 26.1
 Three or more 157 46.0
 History of multiple myeloma 71 22.8
No. treatment series received
 None 20 5.9
 One 70 20.5
 Two 76 22.3
 Three 61 17.9
 Four 25 7.3
 Five or more 89 26.1
 Ever underwent stem cell transplantation 180 52.9
Most recent hematologic response status (n = 321)c
 No response to treatment 20 6.2
 Partial hematologic response or partial remission 126 39.3
 Complete hematologic response or complete remission 140 43.6
 I do not know 35 10.9
  1. GED, General Educational Development; SD, standard deviation
  2. aFrequencies less than 341 are due to missing data; Percentages based on available data
  3. bMultiple response options allowed
  4. cFrequencies and percentages are based on the 321 patients who received at least one treatment series